logo
#

Latest news with #Sundaram

Sund Fin hosts Customer Round Table in Salem
Sund Fin hosts Customer Round Table in Salem

United News of India

time5 days ago

  • Business
  • United News of India

Sund Fin hosts Customer Round Table in Salem

Salem, July 19 (UNI) In a rare and heartfelt gathering that transcended conventional industry events, Sundaram Finance hosted a special Customer Round Table here today, The event brought together a select group of its most longstanding customers — along with the next generation of their families — for an evening of reflection, learning, and emotional connection. Curated with care, this one-of-its-kind initiative was not about business pitches or product showcases. It was about people. About relationships built over decades — some even generations — rooted in mutual respect, shared values, and a deeply personal sense of trust. The Round Table served as an intimate platform to welcome the next generation of customer families into the Sundaram fold, helping them understand not just financial fundamentals, but the spirit of partnership that defines the Sundaram experience. The session was inaugurated by Mr. Kulkarni M J, National Head, Medium & Heavy Commercial Vehicles – Sundaram Finance, who set the tone for the event by reflecting on the company's legacy of walking alongside its customers through changing times. He emphasized that Sundaram's real strength lies not in numbers, but in the depth of its relationships — relationships that are nurtured quietly, consistently, and with sincerity. 'We are here not just to do business, but to stand by our customers — to understand, to guide, and above all, to care. This event is a celebration of the unquestionable loyalty between Sundaram Finance and our customers — a bond that cannot be bought, only built over time with care and integrity", a company release said. In an industry where interactions are often transactional, this kind of event is virtually unheard of. What made it even more powerful was its resonance with the company's core — Sundaram was born out of the desire to serve the underserved, to offer dignity in finance to those often overlooked. Many of the families present at the Round Table began their journey with Sundaram decades ago as first-generation entrepreneurs. Today, they have grown in stature, as has Sundaram. This growth has not been accidental — it has been a shared journey, powered by trust, fairness, and a quiet determination to do things the right way. UNI GV 1615

HUL's Surf Excel liquid detergent eyes premium laundry segment with new product
HUL's Surf Excel liquid detergent eyes premium laundry segment with new product

Mint

time7 days ago

  • Business
  • Mint

HUL's Surf Excel liquid detergent eyes premium laundry segment with new product

New Delhi: Hindustan Unilever Ltd (HUL), a market leader in India's fabric cleaning segment, has launched a new, premium washing liquid variant under its Surf Excel brand, targeting 5% users of liquid detergents to embrace its product. The move comes as Surf Excel, already HUL's largest brand, surpassed ₹ 10,000 crore in sales last fiscal year. The launch reinforces a growing trend of consumer preference for premium products within the laundry market, where liquid detergents are growing four times faster than the overall laundry cleaning market. The innovation, dubbed "Wonder Wash," was initially launched last year in the UK and China by HUL's British parent Unilever, citing a "seismic shift happening in the world of laundry." The product is designed specifically for short cycles and performs in just 15 minutes. Globally, the category is predicted to be worth €2 billion by 2026. In India, it will be sold as Surf Excel Matic Express. It sits at a price premium of 15% over a Surf Matic Liquid. In India, liquids currently account for 10% of the overall laundry cleaning market, which is still dominated by bars and detergent powders. 'Liquids are the fastest growing segment in this market, where the liquids growth is upwards of four times than the rest of the category. The contribution of liquids, overall in the market, is accelerating. But at this point it would be around 10%. Penetration in some South Indian states, which adopted liquids much earlier, is upwards of 60% in urban geographies—i.e. usage at least once a year,' Srinandan Sundaram, executive director, home care, HUL, said in an interview with Mint. Affluent consumers are increasingly purchasing more premium products due to expanded wardrobes and greater use of washing machines. Out of India's 304 million households, 68 million of these use washing machines, and of those, 17 million currently use washing liquids. 'We are seeing more consumers shortening their washing cycles,' Sundaram added. 'Our lens on this launch is to see heavy liquid users upgrading to get a superior experience -people who are using an Express cycle in the washing machine, and those who are also using liquid as the predominant wash solution. We don't intend this to be a short-term launch; this is a multi-year platform for us. We'd be very happy if we are able to get five percent of liquid users to try the new product,' he said. Home care is HUL's largest segment, with annual revenues of ₹ 22,972 crore in FY25, a 5% increase from the previous year. Besides Surf Excel, the company also sells Wheel and Rin laundry wash brands, Comfort fabric conditioner, Vim utensil cleaner, and Domex toilet and floor cleaners. In the March quarter, the home care segment reported mid-single-digit volume growth, led by its double-digit growing liquids portfolio. HUL has basically led the premiumization of the laundry portfolio through new formats and product upgrades, competing with P&G India, which sells the Ariel and Tide brands. In 2020, HUL launched Surf Excel Smart Shots (capsules), its most premium laundry product, and relaunched them earlier this year. According to a company presentation in November, household penetration of Surf Excel liquids quadrupled between calendar years 2019 and 2023, while the turnover tripled. Similarly, between 2023 and 2024, the penetration of Surf Excel Easy Wash Powders jumped four times, and turnover grew tenfold. Abneesh Roy, executive director, Nuvama Institutional Equities, said, 'HUL has seen big success in laundry and its premiumization. This launch will further help in that. With Priya Nair back at the helm as managing director, her past success in heading this business will also help.' Nair, the recently-appointed chief executive officer (CEO) and managing director (MD) of the company, previously served as executive director, home care, HUL, between 2014 and 2020. During her tenure, HUL prioritized building future formats in the home care segment, especially liquid detergents in laundry, with Surf Excel launching the first liquid detergent in the category, according to a July report by Motilal Oswal. Nair also focused on growing the fabric conditioner market in India. For the new launch, HUL has partnered with cricketer Jasprit Bumrah for an ad campaign. The product will be available in general trade and modern trade outlets across South India, and nationwide via e-commerce and quick-commerce platforms.

IOVA FRAUD ALERT: Iovance Biotherapeutics Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 14 Legal Deadline (NASDAQ:IOVA)
IOVA FRAUD ALERT: Iovance Biotherapeutics Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 14 Legal Deadline (NASDAQ:IOVA)

Business Upturn

time22-06-2025

  • Business
  • Business Upturn

IOVA FRAUD ALERT: Iovance Biotherapeutics Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 14 Legal Deadline (NASDAQ:IOVA)

NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting Investors have until July 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Iovance securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sundaram v. Iovance Biotherapeutics, Inc., et al. , No. 25-cv-04177. Why was Iovance Sued for Securities Fraud? Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma treatment Amtagvi in February 2024. Iovance administers Amtagvi at the Company's authorized treatment centers ('ATCs'). As alleged, Iovance repeatedly touted its ATCs as a driver of demand for Amtagvi. In truth, Iovance's ATCs were experiencing long timelines to begin treating patients with Amtagvi, and ineffective patient identification and patient selection for treatment was causing high patient drop-offs at the ATCs. The Stock Declines as the Truth is Revealed On May 8, 2025, Iovance reported disappointing financial results for 1Q25 and announced it was 'revising full-year 2025 revenue guidance.' The Company blamed 'recent launch dynamics,' including slow 'treatment timelines for new ATCs' and 'the variable pace at which ATCs began treating patients,' which 'differs from center to center.' Iovance also blamed the poor results on high 'patient drop-off' due to inadequate 'patient selection' for treatment. On this news, the price of Iovance stock declined more than 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025. Click here if you suffered losses: What Can You Do? If you invested in Iovance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619

IT, ITES sectors to benefit the most with 10-hour shifts
IT, ITES sectors to benefit the most with 10-hour shifts

The Hindu

time18-06-2025

  • Business
  • The Hindu

IT, ITES sectors to benefit the most with 10-hour shifts

Among the biggest beneficiaries of the amendment being proposed to the Karnataka Shops and Commercial Establishment Act, 1961, will be hundreds of companies in the Information Technology and Information Technology-Enabled Services (IT & ITES) sectors offering software services, backend IT services and hardware sales, among others. The State government has proposed to increase the daily working hours to 10 from the current nine hours, besides allowing more overtime hours. A meeting is being held on Wednesday to discuss the proposals. 'The amendment will legitimise the violation of working hours that is already happening in the sector,' said Meenakshi Sundaram, general secretary, CITU, Karnataka, calling it at attempt to 'legalise the illegal act'. Succumbing to pressure Trade unions argued that this was being pushed by the Centre. Mr. Sundaram, said, 'It is unfortunate that the Congress government is not trying to establish a different policy from that of the BJP government. It is succumbing to the pressure of the Centre and compromising the basic rights of the citizens of Karnataka.' Pointing out to a similar exercise by the State government for the factory workers in the State, he said that this would only reduce employment generating potential while helping only profit making. 'Their idea of to keep shops and establishments for long hours hoping to increase the turnover. However, people do not have purchasing capacity. Instead, the government should work towards increasing the income of people.' Mr. Sundaram said that the government has allowed simplification of record maintenance, certification and book maintenance among others. The absence of a strict compliance and monitoring, AITUC State secretary M. Satyananda said, could lead to 'wage theft' where employers could force employees to work for longer hours without increasing wages. 'How can the Labour Department, which faces staff shortage, inspect thousands of commercial establishments? There will be no mechanism to monitor. Increasing hours would reduce the rest period for workers as well,' he said. 'Ease of doing business' Taking a contrary view, president of Karnataka Employers' Association B.C. Prabhakar said that it would help in 'ease of doing business' by exempting establishments employing less than 10 persons from submitting documents. 'In Andhra Pradesh, Haryana, Punjab and Uttarakhand, the exemption for submitting annual returns has been exempted to establishments that hire less than 20 persons,' said Mr. Prabhakar. He said that increase in the cap for daily working hours and extra overtime is a 'progressive measure.' 'It legitimises what is already going on,' he said.

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)
IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Associated Press

time16-06-2025

  • Business
  • Associated Press

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting Investors have until July 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Iovance securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sundaram v. Iovance Biotherapeutics, Inc., et al., No. 25-cv-04177. Why was Iovance Sued for Securities Fraud? Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma treatment Amtagvi in February 2024. Iovance administers Amtagvi at the Company's authorized treatment centers ('ATCs'). As alleged, Iovance repeatedly touted its ATCs as a driver of demand for Amtagvi. In truth, Iovance's ATCs were experiencing long timelines to begin treating patients with Amtagvi, and ineffective patient identification and patient selection for treatment was causing high patient drop-offs at the ATCs. The Stock Declines as the Truth is Revealed On May 8, 2025, Iovance reported disappointing financial results for 1Q25 and announced it was 'revising full-year 2025 revenue guidance.' The Company blamed 'recent launch dynamics,' including slow 'treatment timelines for new ATCs' and 'the variable pace at which ATCs began treating patients,' which 'differs from center to center.' Iovance also blamed the poor results on high 'patient drop-off' due to inadequate 'patient selection' for treatment. On this news, the price of Iovance stock declined more than 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025. Click here if you suffered losses: What Can You Do? If you invested in Iovance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212-789-3619 Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store